As part of a multidisciplinary team at WUSM IBD center and with collaborators at other tertiary IBD centers I have examined various approaches to examine and modulate the pathophysiology of refractory IBD including using biologics and small molecules in combination as well as examining coexisting causes such as the mycobiome. I was a part of the multidisciplinary team at WUSM that led to the discovery of specific species of fungus, Debaryomyces hanseii, in intestinal wounds in CD patients but not in the mucosa of healthy controls.
- Jain U, Ver Heul AM, Xiong S, Gregory MH, Demers EG, Kern JT, Lai CW, Muegge BD, BarisasDAG, Leal-Ekman JS, Deepak P, Ciorba MA, Liu TC, Hogan DA, Debbas P, Braun J, McGovern DPB, Underhill DM, Stappenbeck TS. Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice. Science. 2021 Mar 12;371(6534):1154-1159. PMID: 33707263
- Stalgis C, Deepak P, Mehandru S, Colombel JF. Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. Gastroenterology. 2021 Aug;161(2):394-399.PMID: 33961886
- Alayo QA, Khatiwada A, Patel A, Zulfiqar M, Gremida A, Gutierrez A, Rood RP, Ciorba MA,Christophi GP, Deepak P. Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 Oct 18;27(10):1698-1702. PMID: 34037225
- Alayo QA, Fenster M, Altayar O, Glassner KL, Llano E, Clark-Snustad K, Patel A, Kwapisz L, YarurA, Cohen BL, Ciorba MA, Thomas D, Lee SD, Loftus EV Jr., Fudman DI, Abraham BP, Colombel JF, Deepak P. Systematic Review with Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in IBD. Crohns Colitis 360. 2022 Feb 10;4(1):otac002. PMID: 35310082
- Fan Y, Zhang L, Omidakhsh N, Bohn RL, Thompson JS, Brodovicz KG, Deepak P. Patients With Stricturing or Penetrating Crohn’s Disease Phenotypes Report High Disease Burden and Treatment Needs. Inflamm Bowel Dis. 2023 Jun 1;29(6):914-922. PMID: 35880838